Contact information

Prof. Dr. med. Dr. nat. med. Roland Ullrich

Department I of Internal Medicine

University Hospital of Cologne

Kerpener Straße 62 

50937 Cologne


CMMC - Center for Molecular Medicine Cologne

University of Cologne

Robert-Koch-Straße 21

50931 Cologne


Academic education

1999 - 2005 Medical School (final grade: Sehr gut), University of Cologne; University of Marburg, University of Lyon, Université de Lyon, Université de Paris


Scientific degrees

2006 - 2010 MD-PhD in Molecular Medicine, Center for Molecular Medicine, Cologne (CMMC)
1999 - 2003 MD thesis, Department of Neurosurgery, University of Cologne


Scientific career

2020 Attending physician responsible for personal development of the Medical Clinic I of the University Hospital Cologne (Personaloberarzt)
2020   Executive attending physician, Medical Clinic I of the University Hospital Cologne (Geschäftsführender Oberarzt)
2020 Speaker of the Mildred-Scheel-Nachwuchszentrum: Cancer- and Immuno-Genomics
2019 Professorship (W2) for Molecular Oncology, University Hospital Cologne
2019 Faculty Supervisor of the centralized animal holding facilities at the University Hospital Cologne
2019 Certification of Clinical Sarcoma Center, Cologne by the Deutschen Krebsgesellschaft (one of five first certified centers in Germany)
2017 Attending physician responsible for finances and economic development of the Medical Clinic I of the University Hospital Cologne (Finanzoberarzt)
2017 Head of clinical Sarcoma Center, University Hospital of Cologne
2016 Certified Clinical Research Physician
2015 - present NRW-Junior Research Group Leader at the Center for Molecular Medicine, Cologne (CMMC) and the Medical Clinic I of the University Hospital Cologne
2013 Habilitation for Molecular Medicine, Medical Faculty, University of Cologne
2009 - 2014 Principal Investigator of the Sonderforschungsbereich 832 “Molecular basis and modulation of cellular interactions in the tumor microenvironment” (Projects A6 and Z1)
2009 - 2014 Postdoctoral Research Fellow at the Max-Planck Institute for Neurological Research, Advisor: Prof. Dr. med. Andreas Jacobs


Honors/ Awards/ Memberships

2019 Karin Nolte Award of the German Society for Internal Medicine and SPIGG


  • An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL

    himeric antigen receptor T cell (CAR T) therapy is a potent treatment for relapsed/refractory (r/r) B cell lymphomas but provides lasting remissions in only ∼40% of patients and is associated with serious adverse events. We identify an upregulation of CD80 and/or CD86 in tumor tissue of (r/r)…

  • Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

    Single-agent immunotherapy has shown remarkable efficacy in selected cancer entities and individual patients. However, most patients fail to respond. This is likely due to diverse immunosuppressive mechanisms acting in a concerted way to suppress the host anti-tumor immune response. Combination…

  • In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin’s lymphoma and facilitates ultrasensitive residual disease detection

    Individualizing treatment is key to improve outcome and reduce long-term side-effects in any cancer. In Hodgkin lymphoma (HL), individualization of treatment is hindered by a lack of genomic characterization and technology for sensitive, molecular response assessment. Sequencing of cell-free…

  • Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC

    Anti-angiogenic treatment targeting vascular endothelial growth factor (VEGF)-VEGFR2 signaling has shown limited efficacy in lung cancer patients. Here, we demonstrate that inhibition of VEGFR2 in tumor cells, expressed in ∼20% of non-squamous non-small cell lung cancer (NSCLC) patients, leads to a…

  • Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

    The BCL2 inhibitor venetoclax has been approved to treat different hematological malignancies. Because there is no common genetic alteration causing resistance to venetoclax in chronic lymphocytic leukemia (CLL) and B-cell lymphoma, we asked if epigenetic events might be involved in venetoclax…